Mirae Asset Global Investments Co. Ltd. Sells 657 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mirae Asset Global Investments Co. Ltd. lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 51,782 shares of the medical equipment provider’s stock after selling 657 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Hologic were worth $3,700,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Hologic by 1.4% during the first quarter. Vanguard Group Inc. now owns 27,882,301 shares of the medical equipment provider’s stock valued at $2,141,919,000 after acquiring an additional 381,608 shares in the last quarter. BlackRock Inc. raised its position in shares of Hologic by 1.2% in the first quarter. BlackRock Inc. now owns 23,762,174 shares of the medical equipment provider’s stock valued at $1,917,607,000 after purchasing an additional 282,787 shares during the period. State Street Corp lifted its stake in shares of Hologic by 0.8% in the first quarter. State Street Corp now owns 11,426,634 shares of the medical equipment provider’s stock worth $877,794,000 after buying an additional 94,561 shares during the last quarter. Macquarie Group Ltd. lifted its stake in shares of Hologic by 227.2% in the second quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock worth $435,485,000 after buying an additional 4,363,687 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of Hologic by 8.9% in the third quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider’s stock worth $335,763,000 after buying an additional 393,371 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 3.1 %

Shares of HOLX stock opened at $75.11 on Wednesday. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $87.88. The firm’s fifty day simple moving average is $75.66 and its 200 day simple moving average is $72.46. The firm has a market capitalization of $17.63 billion, a P/E ratio of 35.60, a price-to-earnings-growth ratio of 2.62 and a beta of 1.00. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.03. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.07 EPS. As a group, sell-side analysts predict that Hologic, Inc. will post 4.02 EPS for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the sale, the chief financial officer now owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The disclosure for this sale can be found here. Insiders have sold 32,846 shares of company stock valued at $2,473,443 in the last 90 days. 1.75% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of analyst reports. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $80.00 to $95.00 in a research note on Wednesday, April 3rd. William Blair restated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Evercore ISI boosted their price objective on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Finally, Raymond James boosted their price objective on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Hologic presently has an average rating of “Hold” and an average target price of $87.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.